HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.

PloS one

Volumn 8, Issue 10, 2013, Pages

  Martin, Allison ^a   Moore, Cecilia L ^b   Mallon, Patrick W G ^b   Hoy, Jennifer F ^b   Emery, Sean ^b   Belloso, Waldo H ^b   Phanuphak, Praphan ^b   Ferret, Samuel ^b   Cooper, David A ^b   Boyd, Mark A ^b   Second Line Study Team, ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 PYRROLIDONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHOLESTEROL; LOPINAVIR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; BIOSYNTHESIS; BLOOD; BODY FAT DISTRIBUTION; BODY MASS; CARDIOVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL MODEL; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; BODY FAT DISTRIBUTION; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHOLESTEROL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LIPODYSTROPHY; LOGISTIC MODELS; LOPINAVIR; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PYRROLIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; RITONAVIR; RNA, VIRAL; VIRAL LOAD; VIRUS REPLICATION;

EID: 84902298327     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077138     Document Type: Article

References (0)